Article
Pathology
Shuomeng Du, Han Qu, Ying Zhang, Shihao Zhu, Yang Wang, Shuopeng Zhang, Zhao Wang, Qian Yang, Songbin Fu, Kexian Dong
Summary: This study reveals the role of miR-375 in cisplatin sensitivity of LUAD, showing its ability to promote apoptosis and sensitivity to cisplatin. The analysis of miR-375-related genes and its involvement in the MAPK signaling pathway provide new insights into potential therapeutic strategies and predictive models for cisplatin resistance in LUAD.
PATHOLOGY RESEARCH AND PRACTICE
(2023)
Article
Genetics & Heredity
Ziyao Wang, Lingxuan Zhou, Bisong Chen, Xu Li, Qiuyi Zou, Wei Xu, Li Fang, Anbang Wu, Zheng Li, Yuejun Chen
Summary: Increasing evidence suggests that abnormal expression of microRNAs (miRNAs) is a major factor in chemotherapy resistance in various cancers, but its role in lung adenocarcinoma (LUAD) resistance to cisplatin remains unclear. This study analyzed a microarray dataset to investigate miRNAs related to cisplatin resistance in LUAD. It was found that miR-660/SATB2 axis is a key regulator of cisplatin resistance in LUAD.
Article
Biochemistry & Molecular Biology
Zhen Liu, Jiahao Liu, Yang Li, Hao Wang, Zixi Liang, Xiaojie Deng, Qiaofen Fu, Weiyi Fang, Ping Xu
Summary: The downregulation of VPS33B in tumors is a factor that promotes the progression of lung adenocarcinoma (LUAD). Mechanistic studies show that VPS33B inhibits EGFR Ras/ERK signaling, leading to reduced expression of oncogenic factors like c-Myc. Additionally, the interaction between VPS33B and NESG1 affects LUAD migration and invasion through different signaling pathways.
Article
Biochemistry & Molecular Biology
Feng Jiang, Qiang Shen, Fan Zhang, Jiali Fu, Lijuan Hu, Junjun Wang, Huixin Zhou, Jian Chen, Yumin Wang
Summary: The ADH1C/MAT1A axis may increase cisplatin resistance in LUAD cells, and upregulation of MAT1A is associated with poor prognosis of LUAD.
DNA AND CELL BIOLOGY
(2022)
Article
Chemistry, Multidisciplinary
Qifan Hu, Jing Xu, Lei Wang, Yi Yuan, Ruiguang Luo, Mingxi Gan, Keru Wang, Tao Zhao, Yawen Wang, Tianyu Han, Jian-Bin Wang
Summary: Mitochondrial dysfunction and abnormal energy metabolism are major features of cancer. This study demonstrates that the expression level of SUCLG2 can affect the overall succinylation of LUAD cells, leading to mitochondrial dysfunction. Additionally, succinylation of SUCLG2 on Lys93 enhances its stability and promotes the proliferation and tumorigenesis of LUAD cells. SIRT5 desuccinylates SUCLG2 on Lys93, followed by TRIM21-mediated ubiquitination and degradation, which inhibits mitochondrial function. The findings provide insights into the role of SUCLG2 in tumor progression and offer a theoretical basis for developing anti-cancer drugs targeting SUCLG2.
Article
Oncology
Rodolfo L. Chavez-Dominguez, Mario A. Perez-Medina, Jose S. Lopez-Gonzalez, Miriam Galicia-Velasco, Margarita Matias-Florentino, Santiago Avila-Rios, Uriel Rumbo-Nava, Alfonso Salgado-Aguayo, Claudia Gonzalez-Gonzalez, Dolores Aguilar-Cazares
Summary: Platinum-based chemotherapy remains the cornerstone in the treatment of lung adenocarcinoma, especially for patients without EGFR mutations or those who have developed resistance to targeted therapy. HMGB1 protein plays a role in the intrinsic resistance to cisplatin treatment, contributing to the development of cisplatin resistance in tumor cells and potentially serving as an effective biomarker for increased overall survival of lung adenocarcinoma patients.
FRONTIERS IN ONCOLOGY
(2021)
Article
Multidisciplinary Sciences
Takaya Ishihara, Reiko Ban-Ishihara, Azusa Ota, Naotada Ishihara
Summary: Mitochondria have their own DNA, called mtDNA, which encodes respiratory subunits. Under live imaging, mitochondrial nucleoids actively move and change morphology with mitochondrial membrane fission. The AAA-ATPase protein ATAD3A, anchored to the inner membrane, mediates nucleoid dynamics through ATP hydrolysis.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2022)
Article
Genetics & Heredity
Zheng Yie Yap, Yo Han Park, Saskia B. Wortmann, Adam C. Gunning, Shlomit Ezer, Sukyeong Lee, Lita Duraine, Ekkehard Wilichowski, Kate Wilson, Johannes A. Mayr, Matias Wagner, Hong Li, Usha Kini, Emily Davis Black, Kristin G. Monaghan, James R. Lupski, Sian Ellard, Dominik S. Westphal, Tamar Harel, Wan Hee Yoon
Summary: This study identified 13 individuals from 8 unrelated families with biallelic ATAD3A variants, expanding the allelic spectrum and demonstrating the use of a functional assay in Drosophila for variant interpretation.
Article
Oncology
Xiaosu Chen, Yajing Lv, Kejia Xu, Xiaoshuang Wang, Yujia Zhao, Jia Li, Xuan Qin, Yi Shi, Longlong Wang, Antao Chang, Chongbiao Huang, Rong Xiang
Summary: Chemotherapeutic agents, including cisplatin, have been shown to promote tumor metastasis by influencing the stability of beta-catenin through the key gene DCBLD2. The inhibition of DCBLD2 presents a promising treatment option for preventing chemotherapy-induced metastasis.
Article
Oncology
Rodolfo Chavez-Dominguez, Dolores Aguilar-Cazares, Mario Perez-Medina, Santiago Avila-Rios, Maribel Soto-Nava, Alfonso Mendez-Tenorio, Lorenzo Islas-Vazquez, Jesus J. Benito-Lopez, Miriam Galicia-Velasco, Jose S. Lopez-Gonzalez
Summary: Resistance to cisplatin in lung adenocarcinoma is mainly caused by drug-tolerant-persister (DTP) cells which survive initial cycles of treatment and give rise to acquired resistance clones. In this study, a gene expression signature associated with the emergence of cisplatin-DTP cells was identified. DTP cells deregulate metabolic and proliferative pathways to survive drug insult, with SOCS1 playing a significant role in controlling their proliferation. The expression level of SOCS1 was different between CDDP-susceptible and CDDP-resistant lung adenocarcinoma cell lines, and the downregulation or upregulation of selected genes was associated with overall survival of cisplatin-treated patients.
FRONTIERS IN ONCOLOGY
(2023)
Article
Genetics & Heredity
Yanjun Yin, Lifeng Zhang, Yinchuan Zeng, Diang Chen, Haien Guan, Guoping Ran, Kangming Du
Summary: The study found that the histone ubiquitination-related gene CUL4B plays a significant role in the resistance to cisplatin in lung cancer and overall survival rates of patients. CUL4B is overexpressed in lung cancer tissues and cells, and promotes the proliferation, invasion, and migration of lung cancer cells. High expression of CUL4B is associated with specific signaling pathways and changes in the immune microenvironment.
FRONTIERS IN GENETICS
(2023)
Article
Oncology
Jiali Fu, Jingjing Pan, Xiang Yang, Yan Zhang, Fanggui Shao, Jie Chen, Kate Huang, Yumin Wang
Summary: The study revealed that overexpression of UCA1 in LUAD cells is associated with cisplatin resistance, promoting disease progression and suggesting UCA1 as a potential diagnostic marker and therapeutic target in LUAD patients.
CANCER CELL INTERNATIONAL
(2021)
Article
Pharmacology & Pharmacy
Hanjiao Qin, Ge Zheng, Qiao Li, Luyan Shen
Summary: This study found that DCA can alter the metabolic pattern of cholangiocarcinoma cells under cisplatin stress, increase the production of mitochondrial reactive oxygen species, and promote cell cycle arrest, enhance the expression of antioxidant genes, and activate autophagy. Inhibition of autophagy further enhances the synergistic effect of DCA and cisplatin.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Oncology
Qin Hu, Runtian Wang, Huiyun Ma, Zhouwei Zhang, Qun Xue
Summary: This study analyzed the role of copper-induced cell death in the diagnosis and treatment of lung adenocarcinoma (LUAD) and identified a cupLA panel that is associated with the risk of LUAD occurrence and clinicopathological features. It can guide clinicians in refining LUAD subtypes and making treatment choices.
FRONTIERS IN ONCOLOGY
(2022)
Article
Multidisciplinary Sciences
Jiaqi Liang, Guangyin Zhao, Yunyi Bian, Guoshu Bi, Qihai Sui, Huan Zhang, Haochun Shi, Guangyao Shan, Yiwei Huang, Zhencong Chen, Lin Wang, Cheng Zhan
Summary: This study reveals the important role of HNF4G in cisplatin resistance of lung adenocarcinoma. High expression of HNF4G is positively correlated with cisplatin resistance and poor prognosis in lung adenocarcinoma patients. Mechanistically, HNF4G promotes cisplatin resistance by binding to the MAPK6 promoter region and activating the MAPK6/Akt pathway.
Article
Oncology
Shu-Fen Chiang, Chih-Yang Huang, Tao-Wei Ke, Tsung-Wei Chen, Yu-Ching Lan, Ying-Shu You, William Tzu-Liang Chen, K. S. Clifford Chao
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2019)
Article
Oncology
Tsung-Wei Chen, Kevin Chih-Yang Huang, Shu-Fen Chiang, William Tzu-Liang Chen, Tao-Wei Ke, K. S. Clifford Chao
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2019)
Article
Cell Biology
Chung-Hao Chen, Jing-Wei Lin, Chih-Yang Huang, Yu-Lan Yeh, Chia-Yao Shen, Khan Farheen Badrealam, Tsung-Jung Ho, V. Vijaya Padma, Wei-Wen Kuo
JOURNAL OF CELLULAR PHYSIOLOGY
(2020)
Article
Oncology
Kevin Chih-Yang Huang, Shu-Fen Chiang, William Tzu-Liang Chen, Tsung-Wei Chen, Ching-Han Hu, Pei-Chen Yang, Tao-Wei Ke, K. S. Clifford Chao
Article
Multidisciplinary Sciences
Kevin Chih-Yang Huang, Shu-Fen Chiang, Tsung-Wei Chen, William Tzu-Liang Chen, Pei-Chen Yang, Tao-Wei Ke, K. S. Clifford Chao
SCIENTIFIC REPORTS
(2020)
Article
Oncology
Shu-Fen Chiang, Kevin Chih-Yang Huang, William Tzu-Liang Chen, Tsung-Wei Chen, Tao-Wei Ke, K. S. Clifford Chao
Summary: Immunosurveillance and immunoscavenging induced by preoperative chemoradiotherapy (CCRT) can enhance local control and improve survival rates in locally advanced rectal cancer patients. This study focused on the impact of different genotypes of pattern recognition receptors (PRRs) on therapeutic efficacy in LARC patients receiving CCRT. The findings suggest that the FPR1 genotype may play a role in CCRT-induced anticancer immunity, affecting T lymphocyte migration and infiltration, and could serve as a biomarker for chemo- and radiotherapy outcomes.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2021)
Article
Cell Biology
Kevin Chih-Yang Huang, Shu-Fen Chiang, Pei-Chen Yang, Tao-Wei Ke, Tsung-Wei Chen, Chen-Yu Lin, Hsin-Yu Chang, William Tzu-Liang Chen, Kun-San Clifford Chao
Summary: ATAD3A overexpression is clinically associated with poor prognosis, especially in high-risk colorectal cancer patients receiving adjuvant chemotherapy. ATAD3A plays a crucial role in reducing chemotherapy-induced cancer cell death by interacting with GRP78 protein to alleviate ER stress. Pharmacologic targeting to ATAD3A may enhance antitumor immunity for CRC patients receiving adjuvant chemotherapy.
JOURNAL OF CELLULAR PHYSIOLOGY
(2021)
Article
Oncology
Kevin Chih-Yang Huang, Shu-Fen Chiang, Pei-Chen Yang, Tao-Wei Ke, Tsung-Wei Chen, Ching-Han Hu, Yi-Wen Huang, Hsin-Yu Chang, William Tzu-Liang Chen, K. S. Clifford Chao
Summary: The study evaluates the induction of immunogenic cell death (ICD) by the novel topoisomerase I inhibitor lipotecan for anticancer immunity. Lipotecan significantly increases tumor immunogenicity and promotes therapeutic efficacy of radiotherapy compared to conventional chemoradiotherapy in vivo. These results suggest potential therapeutic strategies to improve the efficacy of chemoradiotherapy in colorectal cancer patients, particularly those with locally advanced rectal cancer.
Article
Multidisciplinary Sciences
Yu-Ting Yen, May Chien, Pei-Yi Wu, Chi-Chang Ho, Chun-Te Ho, Kevin Chih-Yang Huang, Shu-Fen Chiang, K. S. Clifford Chao, William Tzu-Liang Chen, Shih-Chieh Hung
Summary: This study demonstrates that inactivation of protein phosphatase 2A (PP2A) converts cold microsatellite-stable (MSS) tumors into microsatellite-instable (MSI) tumors, promoting cytotoxic T cell infiltration and response to immune checkpoint blockade (ICB).
NATURE COMMUNICATIONS
(2021)
Article
Oncology
Chia-Lin Chang, Kevin Chih-Yang Huang, Tsung-Wei Chen, William Tzu-Liang Chen, Hsuan-Hua Huang, Ya-Ling Liu, Chia-Hui Kuo, K. S. Clifford Chao, Tao-Wei Ke, Shu-Fen Chiang
Summary: The expression of CDC27 is associated with the risk of metastasis in rectal adenocarcinoma patients, and nuclear CDC27 expression is negatively correlated with survival rates. High nuclear CDC27 expression is significantly associated with poorer treatment outcomes. Therefore, CDC27 expression may serve as a potential prognostic marker for tumor progression and chemotherapy treatment in rectal cancer.
Article
Cell Biology
Kevin Chih-Yang Huang, Shu-Fen Chiang, Hsin-Yu Chang, William Tzu-Liang Chen, Pei-Chen Yang, Tsung-Wei Chen, Ji-An Liang, An-Cheng Shiau, Tao-Wei Ke, K. S. Clifford Chao
Summary: This study demonstrates that engineering mesenchymal stem cells (MSCs) to express specific anti-cancer genes can enhance the sensitivity of radiotherapy in colorectal cancer patients. This novel therapeutic strategy not only improves the effectiveness of radiotherapy, but also remodels the tumor microenvironment, making it more suitable for immunotherapy.
CELL DEATH & DISEASE
(2022)
Article
Oncology
Tsung-Wei Chen, Wei-Ze Hung, Shu-Fen Chiang, William Tzu-Liang Chen, Tao-Wei Ke, Ji-An Liang, Chih-Yang Huang, Pei-Chen Yang, Kevin Chih-Yang Huang, K. S. Clifford Chao
Summary: TGF-beta plays a role in chemoresistance in advanced colorectal cancer by regulating PD-L1 expression. TAMs and TUB are the main components that regulate PD-L1 expression within the immunosuppressive tumor microenvironment.
Article
Multidisciplinary Sciences
Kevin Chih-Yang Huang, Tao-Wei Ke, Jia-Yi Chen, Wei-Ze Hong, Shu-Fen Chiang, Chia-Ying Lai, Tsung-Wei Chen, Pei-Chen Yang, Liang-Chi Chen, Ji-An Liang, William Tzu-Liang Chen, K. S. Clifford Chao
Summary: This study found that patients with colorectal cancer who carry the TLR1-N248S polymorphism may have a higher risk of distant metastasis and poorer response to adjuvant chemotherapy. Defective TLR1 affects dendritic cell maturation and immune cell infiltration, while TLR1/2 agonists enhance the efficacy of chemotherapy and increase tumor-infiltrating immune cells.
SCIENTIFIC REPORTS
(2023)
Article
Oncology
Kevin Chih-Yang Huang, Shu-Fen Chiang, Tao-Wei Ke, Tsung-Wei Chen, Ching-Han Hu, Pei-Chen Yang, Hsin-Yu Chang, Ji-An Liang, William Tzu-Liang Chen, K. S. Clifford Chao
Summary: The study found a negative correlation between PD-L1 promoter methylation and tumor PD-L1 expression in locally advanced colorectal cancer patients, identifying it as an independent biomarker. PD-L1 methylation was associated with decreased disease-free survival and classified as an independent prognostic factor for poor 5-year DFS. The immunomodulatory agent DNMTi improved the efficacy of radiotherapy and anti-PD-L1 immunotherapy by inducing tumor PD-L1 expression and enhancing immune responses.
Article
Oncology
Kevin Chih-Yang Huang, Shu-Fen Chiang, Tao-Wei Ke, William Tzu-Liang Chen, Tsung-Wei Chen, Kun-San Clifford Chao
CANCER GENOMICS & PROTEOMICS
(2020)